<DOC>
	<DOCNO>NCT00338117</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness relatively high dose galantamine , 32 mg /day three-times daily dosage , compare placebo treat patient Alzheimer 's disease .</brief_summary>
	<brief_title>Safety Efficacy High Dose , Rapid Titration Galantamine Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>Alzheimer 's disease progressive degenerative brain disorder affect memory , well ability concentrate , reason , think abstract form . This study design examine effectiveness safety galantamine ( galant . ) hydrobromide relatively high dose , compare treatment placebo , men woman Alzheimer 's disease . Approximately 600 patient screen . This double-blind study , i.e. , neither patient investigator know treatment give . Before start double-blind phase , patient randomly assign receive either galantamine hydrobromide placebo ( i.e. , active drug ) . The dose increase weekly , high rate currently recommend label , stable daily dose 32 mg galantamine reach . All patient take treatment ( galantamine placebo ) 3 time day . All patient complete blinded phase study permit enter open-label phase , treatment make know investigator patient . During additional 24-week phase , patient receive treatment galantamine hydrobromide . The effectiveness study treatment ( galantamine hydrobromide placebo ) assess use several measure include Mini Mental State Examination ( MMSE ) score . The MMSE consist 12 question task design assess severity Alzheimer 's disease . Additional measure include European Alzheimer Disease Assessment Scale cognitive score ( EURO-ADAS-cog ) , Clinician 's Interview Based Impression Change ( CIBIC ) plus , Nurses ' Observation Scale Geriatric Patients ( NOSGER ) . Safety tolerability assess use physical ( full brief ) examination , adverse event report , clinical laboratory measure , 12-lead ECG result . Galant . take orally tablet 3 time day meal . Patients start treatment total 8 mg galantamine . The dose increase weekly daily cumulative dose 32 mg ( 40 mg Gal HBr ) .This dose high titration schedule 4 time rapid 16 mg 24 mg maintenance dose 4-weekly titration step specify US label . Each phase 5-week titration period . After 5 week , patient continue receive 40 mg .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Have meeting diagnostic criterion Alzheimer 's disease mild moderate dementia measure Mini Mental State Examination ( MMSE ) score live daily visit responsible caregiver . Parkinson 's disease Pick 's disease secondary pseudodementias currently diagnose epilepsy history endocrine disorder significant heart disease drug alcohol abuse kidney liver dysfunction woman childbearing potential unless appropriate birthcontrol method use sensitivity study drug .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Dementia</keyword>
	<keyword>neurodegenerative disorder</keyword>
	<keyword>impairment memory</keyword>
	<keyword>galantamine</keyword>
	<keyword>galanthamine</keyword>
	<keyword>acetylcholinesterase inhibitor</keyword>
	<keyword>Mini Mental State Examination score</keyword>
</DOC>